Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
Translational Stroke Research
|
June 9, 2021
Natural Killer Cells Are Present in Rag1<sup>-/-</sup> Mice and Promote Tissue Damage During the Acute Phase of Ischemic Stroke
Leoni Rolfes, Tobias Ruck, Christina David, et al.
Therapeutic Advances in Neurological Disorders
|
March 26, 2026
Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis
Patricia Kirschner, Franz F Konen, Franziska Axhausen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
October 20, 2021
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
Melanie Eschborn, Marc Pawlitzki, Timo Wirth, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
December 4, 2025
Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort
Franz Felix Konen, Steffen Pfeuffer, Konstantin Fritz Jendretzky, et al.
Neurological Research and Practice
|
July 17, 2025
Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis
Franz Felix Konen, Torsten Witte, Diana Ernst, et al.
Cellular and Molecular Gastroenterology and Hepatology
|
August 16, 2022
Deficiency of the Two-Pore Potassium Channel KCNK9 Impairs Intestinal Epithelial Cell Survival and Aggravates Dextran Sodium Sulfate-Induced Colitis
Steffen Pfeuffer, Thomas Müntefering, Leoni Rolfes, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 6, 2025
Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis
Pia Winter, Franziska Axhausen, Stephanie Wolff, et al.
The EMBO Journal
|
September 24, 2019
Prdx4 limits caspase-1 activation and restricts inflammasome-mediated signaling by extracellular vesicles
Simone Lipinski, Steffen Pfeuffer, Philipp Arnold, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
July 15, 2021
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.
Annals of Neurology
|
November 25, 2024
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab
Sven G Meuth, Stephanie Wolff, Anna Mück, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
Translational Stroke Research
|
June 9, 2021
Natural Killer Cells Are Present in Rag1<sup>-/-</sup> Mice and Promote Tissue Damage During the Acute Phase of Ischemic Stroke
Leoni Rolfes, Tobias Ruck, Christina David, et al.
Therapeutic Advances in Neurological Disorders
|
March 26, 2026
Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis
Patricia Kirschner, Franz F Konen, Franziska Axhausen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
October 20, 2021
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
Melanie Eschborn, Marc Pawlitzki, Timo Wirth, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
December 4, 2025
Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort
Franz Felix Konen, Steffen Pfeuffer, Konstantin Fritz Jendretzky, et al.
Neurological Research and Practice
|
July 17, 2025
Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis
Franz Felix Konen, Torsten Witte, Diana Ernst, et al.
Cellular and Molecular Gastroenterology and Hepatology
|
August 16, 2022
Deficiency of the Two-Pore Potassium Channel KCNK9 Impairs Intestinal Epithelial Cell Survival and Aggravates Dextran Sodium Sulfate-Induced Colitis
Steffen Pfeuffer, Thomas Müntefering, Leoni Rolfes, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 6, 2025
Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis
Pia Winter, Franziska Axhausen, Stephanie Wolff, et al.
The EMBO Journal
|
September 24, 2019
Prdx4 limits caspase-1 activation and restricts inflammasome-mediated signaling by extracellular vesicles
Simone Lipinski, Steffen Pfeuffer, Philipp Arnold, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
July 15, 2021
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.
Annals of Neurology
|
November 25, 2024
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab
Sven G Meuth, Stephanie Wolff, Anna Mück, et al.
Page
of 7